**999-P: Six Months at-Home Hybrid Closed-Loop Vs. Manual Insulin Delivery with Finger-Stick Blood Glucose Monitoring in Adults with Type 1 Diabetes: A Randomized Controlled Trial**

*McAuley, S. A., Lee, M. H., Paldus, B., Vogrin, S., Abraham, M. B., Bach, L., Burt, M., Cohen, N., Colman, P. G., Davis, E. A., Hendrieckx, C., Bock, M. D., Holmes-Walker, J., Kaye, J., Kumareswaran, K., Macisaac, R., McCallum, R. W., Sims, C. M., Speight, J., Stranks, S., Trawley, S., Sundararajan, V., Ward, G., Keech, A. C., Jenkins, A., Jones, T. I. M., & Oneal, D. N.*

This study set out to examine glycaemic and psychosocial outcomes in adults with type 1 diabetes using hybrid closed loop system (HCL), in comparison to individuals using manual insulin dosing with self-monitoring of blood glucose (SMBG).

HCL and control groups were well balanced at baseline. At 26 weeks, mean CGM time in range with HCL was greater, with reduced high and low glucose time and lower HbA1c.

HCL provided a significant and sustained glycaemic benefit compared with standard therapy. Results will inform potential users and health professionals and a cost-benefit analysis may facilitate HCL access.